Cerus Corporation Announces Agreement With Health Canada for Regulatory Submission of the INTERCEPT Blood System for Platelets and Plasma
Published: Nov 06, 2013
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has reached agreement with Health Canada regarding a regulatory submission for the INTERCEPT Blood System for platelets and plasma. Cerus plans to file with Health Canada for both products in the first half of 2014. Health Canada is the federal department in Canada that is responsible for review and authorization of drug, device and health products. Canada is supported by two blood services, Hema Quebec for the province of Quebec and Canadian Blood Services for the remainder of the country.
Help employers find you! Check out all the jobs and post your resume.